Российский опыт применения подкожной формы препарата трастузумаб

Е В Лубенникова,И. П. Ганьшина,А. Н. Луд,Д. В. Комов,И. В. Колядина,Я. В. Вишневская,И. К. Воротников,Д. Л. Строяковский,Н. А. Савелов,В. Ф. Семиглазов,А. Г. Манихас, А. В. Ошейчик, Т. Б. Стрельникова, К. Р. Зейналова,Л Г Жукова

Медицинский совет（2017）

Cited 0|Views5

No score

Abstract

The HannaH study showed that neoadjuvante-adjuvant subcutaneous and intravenous trastuzumab have similar efficacy and tolerability in patients with early HER2-positive breast cancer. The analysis of the results of the subcutaneous and intravenous trastuzumab usage in Russian population showed the favorable association between tpCR anf EFS. tpCR achiviement is associated with clinical benefit in HER2 positive breast cancer. For patients with difficult venous access who do not require intravenous chemotherapy currently, Subcutaneous trastuzumab allows to receive effective treatment without the risk of complications, which involves catheterization of a Central vein.

Translated text

Key words

subcutaneous trastuzumab,russian

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined